Market Capitalization (Millions $) |
31,963 |
Shares
Outstanding (Millions) |
146 |
Employees |
9,610 |
Revenues (TTM) (Millions $) |
9,836 |
Net Income (TTM) (Millions $) |
1,162 |
Cash Flow (TTM) (Millions $) |
-2,405 |
Capital Exp. (TTM) (Millions $) |
311 |
Biogen Inc
Biogen Idec creates new standards of care in oncology and immunology. As a global
leader in the development, manufacturing, and commercialization of novel therapies,
we transform scientific discoveries into advances in human healthcare. We currently
have four commercial products: AVONEX' (Interferon beta-1a) for the treatment
of relapsing multiple sclerosis, also known as MS, RITUXAN' (rituximab)'and ZEVALIN'
(ibritumomab tiuxetan), both of which treat certain B-cell non-Hodgkin's lymphomas,
also referred to as B-cell NHLs, and AMEVIVE' (alefacept)'for the treatment of
adult patients with moderate-to-severe chronic plaque psoriasis who are candidates
for systemic therapy or phototherapy.
Company Address: 225 Binney Street Cambridge 2142 MA
Company Phone Number: 679-2000 Stock Exchange / Ticker: NASDAQ BIIB
|